<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00006164</url>
  </required_header>
  <id_info>
    <org_study_id>HALT C</org_study_id>
    <secondary_id>N01-DK-9-2328</secondary_id>
    <secondary_id>N01-DK-9-2323</secondary_id>
    <secondary_id>N01-DK-9-2324</secondary_id>
    <secondary_id>N01-DK-9-2325</secondary_id>
    <secondary_id>N01-DK-9-2326</secondary_id>
    <secondary_id>N01-DK-9-2321</secondary_id>
    <secondary_id>N01-DK-9-2327</secondary_id>
    <secondary_id>N01-DK-9-2319</secondary_id>
    <secondary_id>N01-DK-9-2318</secondary_id>
    <secondary_id>N01-DK-9-2320</secondary_id>
    <secondary_id>N01-DK-9-2322</secondary_id>
    <nct_id>NCT00006164</nct_id>
    <nct_alias>NCT00006139</nct_alias>
  </id_info>
  <brief_title>Long Term Interferon for Patients Who Did Not Clear Hepatitis C Virus With Standard Treatment</brief_title>
  <acronym>HALT-C</acronym>
  <official_title>Hepatitis C Antiviral Long-term Treatment Against Cirrhosis Trial (HALT-C)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute on Minority Health and Health Disparities (NIMHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The HALT-C Trial is a National Institute of Diabetes and Digestive and Kidney Diseases
      sponsored, randomized clinical trial of long-term use of Peginterferon alfa-2a (pegylated
      interferon) in patients who failed to respond to prior interferon treatment. All patients who
      enter the trial will be treated for 6 months with Peginterferon alfa-2a and Ribavirin.
      Patients who respond to this 6 month treatment will continue to be treated for an additional
      6 months.

      Patients who do not respond to this treatment will be eligible for the long-term maintenance
      phase of this study where patients will be randomly selected to be treated with Peginterferon
      alfa-2a or to discontinue treatment for 3.5 years. Patients in both arms of this study will
      be followed closely with quarterly study visits.

      The combination of peginterferon plus ribavirin has recently been approved by the FDA for
      treatment of chronic hepatitis C. Patients who remain HCV-RNA positive after being treated
      for at least 6 months with peginterferon and ribavirin outside of this study may be eligible
      to directly enter the randomized portion of the HALT-C Trial.

      The HALT-C study is designed to determine if continuing interferon long-term over several
      years will suppress Hepatitis C virus, prevent progression to cirrhosis, prevent liver cancer
      and reduce the need for liver transplantation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2000</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">April 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression of Liver Disease as Indicated by Death, Hepatic Decompensation, Hepatocellular Carcinoma, or for Patients With Noncirrhotic Fibrosis at Baseline, an Increase in the Ishak Hepatic Fibrosis Score of 2 or More Points</measure>
    <time_frame>1400 days (3.85 years) post randomization</time_frame>
    <description>Progression of liver disease within 1400 days as indicated by death, hepatic decompensation (variceal hemorrhage; ascites; spontaneous bacterial peritonitis; hepatic encephalopathy), hepatocellular carcinoma, a Child-Turcotte-Pugh (CTP) score of 7 or more on two consecutive study visits (score range 5-15, higher score indicates greater decompensation), or for patients with noncirrhotic fibrosis at baseline, an increase in Ishak hepatic fibrosis score (range 0-6, higher score indicates greater fibrosis) of at least 2 points by assessment of a liver-biopsy specimen obtained during the study</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Increase in Ishak Fibrosis Score by 2 Points or More at 2 or 4 Year Biopsies</measure>
    <time_frame>1400 days (3.85 years) post randomization</time_frame>
    <description>For patients with noncirrhotic fibrosis at baseline, an increase in Ishak hepatic fibrosis score (range 0-6, higher score indicates greater fibrosis) of at least 2 points by assessment of a liver-biopsy specimen obtained during the study (collected at Year 2 and Year 4 biopsies, 1.5 and 3.5 years after randomization)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Death From Any Cause</measure>
    <time_frame>1400 days (3.85 years) post randomization</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Development of Hepatocellular Carcinoma (HCC)</measure>
    <time_frame>1400 days (3.85 years) post randomization</time_frame>
    <description>A diagnosis of development of hepatocellular carcinoma (HCC) was based on either
Histology showing HCC (from a biopsy, surgery, or autopsy) or
A new hepatic defect on imaging with an alpha-fetoproteion (AFP) level rising to &gt; 1,000 ng/ml.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Child-Turcotte-Pugh (CTP) Score of 7 or Higher at Two Consecutive Study Visits</measure>
    <time_frame>1400 days (3.85 years) post randomization</time_frame>
    <description>Child-Turcotte-Pugh (CTP) score of 7 or more on two consecutive study visits (score range 5-15, higher score indicates greater hepatic decompensation)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Variceal Hemorrhage</measure>
    <time_frame>1400 days (3.85 years) post randomization</time_frame>
    <description>A gastrointestinal hemorrhage which is believed by the investigator to be due to bleeding esophageal or gastric varices. In general, an endoscopy will have been performed and will have revealed either direct evidence of variceal bleeding (bleeding varix, red wale sign) or historical evidence for significant upper gastro-intestinal bleeding plus upper endoscopy revealing moderate varices and no other site of bleeding is identified</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ascites</measure>
    <time_frame>1400 days (3.85 years) post randomization</time_frame>
    <description>Any abdominal fluid which is:
Mild, moderate or marked on ultrasound; or
Progressive on serial physical examinations; or
Requires diuretic therapy. To meet the definition of ascites, abdominal fluid that is &quot;mild&quot; (&quot;barely detectable&quot;) on physical examination requires ultrasound confirmation that is &quot;mild&quot;, &quot;moderate&quot; or &quot;marked&quot; ascites. Ultrasound reports of minimal fluid around the liver do not meet the definition.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Spontaneous Bacterial Peritonitis</measure>
    <time_frame>1400 days (3.85 years) post randomization</time_frame>
    <description>Any episode of spontaneous ascitic infection diagnosed on the basis of elevated neutrophil count (&gt; 250/ml) in paracentesis fluid or positive bacterial cultures and clinical diagnosis in the absence of white blood cell (WBC) availability.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hepatic Encephalopathy</measure>
    <time_frame>1400 days (3.85 years) post randomization</time_frame>
    <description>Any mental status alteration which is deemed by the investigator to be due to portosystemic encephalopathy, whether occurring during a provoked episode (GI bleeding, diuretics, usual sedative doses), or spontaneously (without apparent cause).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serious Adverse Events</measure>
    <time_frame>1400 days (3.85 years) post randomization</time_frame>
    <description>A serious adverse event (SAE) is an untoward medical occurrence that results in any of the following:
Death
Is life threatening (risk of death at the time of the event)
Requires in-patient hospitalization or prolongation of existing hospitalization
Results in persistent or significant disability/incapacity
Congenital abnormality or birth defect
Trial outcomes (except death) were not considered serious adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Fibrosis From Baseline at Year 2 or Year 4 Biopsy.</measure>
    <time_frame>1400 days (3.85 years) post randomization</time_frame>
    <description>Change in Ishak hepatic fibrosis score (range 0-6, higher score indicates greater fibrosis) by assessment of a liver-biopsy specimen obtained during the study (collected at baseline, Year 2 and Year 4 biopsies, 1.5 and 3.5 years after randomization)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presumed Hepatocellular Carcinoma (HCC)</measure>
    <time_frame>1400 days (3.85 years) post randomization</time_frame>
    <description>Presumed HCC was considered when histology was not available and alpha-fetoprotein (AFP) is &lt;1000 ng/ml, if:
A new hepatic lesion was shown on ultrasound and 1 additional imaging showed a hepatic lesion with characteristics of HCC.
AFP&gt; upper limit of normal (ULN) and 2 imaging studies showed a hepatic lesion with characteristics of HCC.
A progressively enlarging hepatic lesion starting as a new defect resulting in patient death.
A new hepatic defect with at least 1 characteristic scan and:
Increase in size over time or
Increasing AFP rising to a level of &gt;200 ng/ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF-36 Vitality Summary Score</measure>
    <time_frame>0.5, 1.5, 2.5, and 3.5 years after randomization</time_frame>
    <description>Change from baseline to years 0.5, 1.5, 2.5, and 3.5 in Short Form Health Survey (SF-36) Vitality summary score. The SF-36 Vitality summary score is the sum of 4 individual scores. It is scaled from 0 to 100 with a score of 0 equivalent to maximum disability and a score of 100 equivalent to no disability. A negative value indicates a decrease in quality of life from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF-36 Physical Function Summary Score</measure>
    <time_frame>0.5, 1.5, 2.5, and 3.5 years after randomization</time_frame>
    <description>Change from baseline to years 0.5, 1.5, 2.5, and 3.5 in Short Form Health Survey (SF-36) Physical Function summary score. The SF-36 Physical Function summary score is the sum of 10 individual scores. It is scaled from 0 to 100 with a score of 0 equivalent to maximum disability and a score of 100 equivalent to no disability. A negative value indicates a decrease in quality of life from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF-36 Mental Health Summary Score</measure>
    <time_frame>0.5, 1.5, 2.5, and 3.5 years after randomization</time_frame>
    <description>Change from baseline to years 0.5, 1.5, 2.5, and 3.5 in Short Form Health Survey (SF-36) Mental Health summary score. The SF-36 Mental Health summary score is the sum of 5 individual scores. It is scaled from 0 to 100 with a score of 0 equivalent to maximum disability and a score of 100 equivalent to no disability. A negative value indicates a decrease in quality of life from baseline.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1050</enrollment>
  <condition>Chronic Hepatitis c</condition>
  <condition>Cirrhosis, Liver</condition>
  <condition>Fibrosis, Liver</condition>
  <condition>Hepatic Cirrhosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Peg-interferon alfa-2a 90 mcg/week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard of care followup</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peginterferon alfa-2a + Ribavirin</intervention_name>
    <description>Peginterferon alfa-2a 180 mcg/week injection, for 24 weeks, plus 1000-1200 mg Ribavirin oral (prescribed according to weight &lt;75 kg, &gt;75 kg) daily in two divided doses for 24 weeks</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>Pegasys (Hoffman-La Roche)</other_name>
    <other_name>Copegus (Hoffman-La Roche)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peginterferon alfa-2a</intervention_name>
    <description>90 mcg/week injection, for 3.5 years</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Pegasys (Hoffman-La Roche)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age at entry at least 18 years.

          -  Positive for Hepatitis C.

          -  Previous treatment with any interferon or interferon and ribavirin for at least 3
             months.

          -  Documented non-response to treatment with interferon.

          -  A liver biopsy demonstrating significant liver scarring.

        Exclusion Criteria:

          -  No other liver disease.

          -  No unstable major medical diseases or conditions.

          -  No major complications of cirrhosis.

          -  No recent abuse of alcohol or illicit drugs.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gregory T. Everson, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCHSC (University of Colorado)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Adrian M. Di Bisceglie, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Louis University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>William M. Lee, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas, Southwestern Medical Center at Dallas</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marc Ghany, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>LDS, NIDDK, NIH</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jules L. Dienstag, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mitchell Shiffman, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical College of Virginia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anna Lok, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tim Morgan, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California-Irvine/VA Medical Center-Long Beach</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Karen Lindsay, M.D., M.M.M.</last_name>
    <role>Principal Investigator</role>
    <affiliation>USC School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gyongyi Szabo, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMass Medical School</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California-Irvine/VA Medical Center-Long Beach</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90822</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>USC School of Medicine</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCHSC (University of Colorado)</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Connecticut Health Center</name>
      <address>
        <city>Farmington</city>
        <state>Connecticut</state>
        <zip>06030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lds, Niddk, Nih</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1800</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMass Memorial HealthCare, University Campus</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Louis University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern - Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390-9195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Virginia</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298-0341</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Lee WM, Dienstag JL, Lindsay KL, Lok AS, Bonkovsky HL, Shiffman ML, Everson GT, Di Bisceglie AM, Morgan TR, Ghany MG, Morishima C, Wright EC, Everhart JE; HALT-C Trial Group. Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clin Trials. 2004 Oct;25(5):472-92.</citation>
    <PMID>15465617</PMID>
  </reference>
  <results_reference>
    <citation>Di Bisceglie AM, Shiffman ML, Everson GT, Lindsay KL, Everhart JE, Wright EC, Lee WM, Lok AS, Bonkovsky HL, Morgan TR, Ghany MG, Morishima C, Snow KK, Dienstag JL; HALT-C Trial Investigators. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med. 2008 Dec 4;359(23):2429-41. doi: 10.1056/NEJMoa0707615.</citation>
    <PMID>19052125</PMID>
  </results_reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 8, 2000</study_first_submitted>
  <study_first_submitted_qc>August 8, 2000</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 9, 2000</study_first_posted>
  <results_first_submitted>June 9, 2009</results_first_submitted>
  <results_first_submitted_qc>July 30, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 4, 2009</results_first_posted>
  <last_update_submitted>April 11, 2018</last_update_submitted>
  <last_update_submitted_qc>April 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>liver disease</keyword>
  <keyword>hepatitis c virus</keyword>
  <keyword>antiviral agent</keyword>
  <keyword>cirrhosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Peginterferon Alfa-2a 90 mcg/Week</title>
          <description>Treatment with Peginterferon alfa-2a 90 mcg administered once weekly for an additional 42 months</description>
        </group>
        <group group_id="P2">
          <title>Standard of Care Followup</title>
          <description>Stop any peginterferon alfa-2a/ribavirin therapy and followed prospectively for an additional 42 months without treatment</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="517"/>
                <participants group_id="P2" count="533"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="447">70 Withdrew or were lost to followup; 158 Discontinued peginterferon but were followed</participants>
                <participants group_id="P2" count="452">81 Withdrew or were lost to followup; 9 took peginterferon outside of protocol</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
                <participants group_id="P2" count="81"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrew or lost to follow-up</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
                <participants group_id="P2" count="81"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Peginterferon Alfa-2a 90 mcg/Week</title>
          <description>Treatment with Peginterferon alfa-2a 90 mcg administered once weekly for an additional 42 months</description>
        </group>
        <group group_id="B2">
          <title>Standard of Care Followup</title>
          <description>Stop any peginterferon alfa-2a/ribavirin therapy and followed prospectively for an additional 42 months without treatment</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="517"/>
            <count group_id="B2" value="533"/>
            <count group_id="B3" value="1050"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="489"/>
                    <measurement group_id="B2" value="511"/>
                    <measurement group_id="B3" value="1000"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.1" spread="7.3"/>
                    <measurement group_id="B2" value="50.1" spread="7.0"/>
                    <measurement group_id="B3" value="50.6" spread="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="155"/>
                    <measurement group_id="B2" value="150"/>
                    <measurement group_id="B3" value="305"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="362"/>
                    <measurement group_id="B2" value="383"/>
                    <measurement group_id="B3" value="745"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="517"/>
                    <measurement group_id="B2" value="533"/>
                    <measurement group_id="B3" value="1050"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression of Liver Disease as Indicated by Death, Hepatic Decompensation, Hepatocellular Carcinoma, or for Patients With Noncirrhotic Fibrosis at Baseline, an Increase in the Ishak Hepatic Fibrosis Score of 2 or More Points</title>
        <description>Progression of liver disease within 1400 days as indicated by death, hepatic decompensation (variceal hemorrhage; ascites; spontaneous bacterial peritonitis; hepatic encephalopathy), hepatocellular carcinoma, a Child-Turcotte-Pugh (CTP) score of 7 or more on two consecutive study visits (score range 5-15, higher score indicates greater decompensation), or for patients with noncirrhotic fibrosis at baseline, an increase in Ishak hepatic fibrosis score (range 0-6, higher score indicates greater fibrosis) of at least 2 points by assessment of a liver-biopsy specimen obtained during the study</description>
        <time_frame>1400 days (3.85 years) post randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Peginterferon Alfa-2a 90 mcg/Week</title>
            <description>Treatment with Peginterferon alfa-2a 90 mcg administered once weekly for an additional 42 months</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care Followup</title>
            <description>Stop any peginterferon alfa-2a/ribavirin therapy and followed prospectively for an additional 42 months without treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Progression of Liver Disease as Indicated by Death, Hepatic Decompensation, Hepatocellular Carcinoma, or for Patients With Noncirrhotic Fibrosis at Baseline, an Increase in the Ishak Hepatic Fibrosis Score of 2 or More Points</title>
          <description>Progression of liver disease within 1400 days as indicated by death, hepatic decompensation (variceal hemorrhage; ascites; spontaneous bacterial peritonitis; hepatic encephalopathy), hepatocellular carcinoma, a Child-Turcotte-Pugh (CTP) score of 7 or more on two consecutive study visits (score range 5-15, higher score indicates greater decompensation), or for patients with noncirrhotic fibrosis at baseline, an increase in Ishak hepatic fibrosis score (range 0-6, higher score indicates greater fibrosis) of at least 2 points by assessment of a liver-biopsy specimen obtained during the study</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="517"/>
                <count group_id="O2" value="533"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="157"/>
                    <measurement group_id="O2" value="157"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Increase in Ishak Fibrosis Score by 2 Points or More at 2 or 4 Year Biopsies</title>
        <description>For patients with noncirrhotic fibrosis at baseline, an increase in Ishak hepatic fibrosis score (range 0-6, higher score indicates greater fibrosis) of at least 2 points by assessment of a liver-biopsy specimen obtained during the study (collected at Year 2 and Year 4 biopsies, 1.5 and 3.5 years after randomization)</description>
        <time_frame>1400 days (3.85 years) post randomization</time_frame>
        <population>Patients with Ishak fibrosis score &lt;5 at baseline and at least one follow-up biopsy</population>
        <group_list>
          <group group_id="O1">
            <title>Peginterferon Alfa-2a 90 mcg/Week</title>
            <description>Treatment with Peginterferon alfa-2a 90 mcg administered once weekly for an additional 42 months</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care Followup</title>
            <description>Stop any peginterferon alfa-2a/ribavirin therapy and followed prospectively for an additional 42 months without treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Increase in Ishak Fibrosis Score by 2 Points or More at 2 or 4 Year Biopsies</title>
          <description>For patients with noncirrhotic fibrosis at baseline, an increase in Ishak hepatic fibrosis score (range 0-6, higher score indicates greater fibrosis) of at least 2 points by assessment of a liver-biopsy specimen obtained during the study (collected at Year 2 and Year 4 biopsies, 1.5 and 3.5 years after randomization)</description>
          <population>Patients with Ishak fibrosis score &lt;5 at baseline and at least one follow-up biopsy</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="273"/>
                <count group_id="O2" value="274"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                    <measurement group_id="O2" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Death From Any Cause</title>
        <time_frame>1400 days (3.85 years) post randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Peginterferon Alfa-2a 90 mcg/Week</title>
            <description>Treatment with Peginterferon alfa-2a 90 mcg administered once weekly for an additional 42 months</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care Followup</title>
            <description>Stop any peginterferon alfa-2a/ribavirin therapy and followed prospectively for an additional 42 months without treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Death From Any Cause</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="517"/>
                <count group_id="O2" value="533"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Development of Hepatocellular Carcinoma (HCC)</title>
        <description>A diagnosis of development of hepatocellular carcinoma (HCC) was based on either
Histology showing HCC (from a biopsy, surgery, or autopsy) or
A new hepatic defect on imaging with an alpha-fetoproteion (AFP) level rising to &gt; 1,000 ng/ml.</description>
        <time_frame>1400 days (3.85 years) post randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Peginterferon Alfa-2a 90 mcg/Week</title>
            <description>Treatment with Peginterferon alfa-2a 90 mcg administered once weekly for an additional 42 months</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care Followup</title>
            <description>Stop any peginterferon alfa-2a/ribavirin therapy and followed prospectively for an additional 42 months without treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Development of Hepatocellular Carcinoma (HCC)</title>
          <description>A diagnosis of development of hepatocellular carcinoma (HCC) was based on either
Histology showing HCC (from a biopsy, surgery, or autopsy) or
A new hepatic defect on imaging with an alpha-fetoproteion (AFP) level rising to &gt; 1,000 ng/ml.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="517"/>
                <count group_id="O2" value="533"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Child-Turcotte-Pugh (CTP) Score of 7 or Higher at Two Consecutive Study Visits</title>
        <description>Child-Turcotte-Pugh (CTP) score of 7 or more on two consecutive study visits (score range 5-15, higher score indicates greater hepatic decompensation)</description>
        <time_frame>1400 days (3.85 years) post randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Peginterferon Alfa-2a 90 mcg/Week</title>
            <description>Treatment with Peginterferon alfa-2a 90 mcg administered once weekly for an additional 42 months</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care Followup</title>
            <description>Stop any peginterferon alfa-2a/ribavirin therapy and followed prospectively for an additional 42 months without treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Child-Turcotte-Pugh (CTP) Score of 7 or Higher at Two Consecutive Study Visits</title>
          <description>Child-Turcotte-Pugh (CTP) score of 7 or more on two consecutive study visits (score range 5-15, higher score indicates greater hepatic decompensation)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="517"/>
                <count group_id="O2" value="533"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Variceal Hemorrhage</title>
        <description>A gastrointestinal hemorrhage which is believed by the investigator to be due to bleeding esophageal or gastric varices. In general, an endoscopy will have been performed and will have revealed either direct evidence of variceal bleeding (bleeding varix, red wale sign) or historical evidence for significant upper gastro-intestinal bleeding plus upper endoscopy revealing moderate varices and no other site of bleeding is identified</description>
        <time_frame>1400 days (3.85 years) post randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Peginterferon Alfa-2a 90 mcg/Week</title>
            <description>Treatment with Peginterferon alfa-2a 90 mcg administered once weekly for an additional 42 months</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care Followup</title>
            <description>Stop any peginterferon alfa-2a/ribavirin therapy and followed prospectively for an additional 42 months without treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Variceal Hemorrhage</title>
          <description>A gastrointestinal hemorrhage which is believed by the investigator to be due to bleeding esophageal or gastric varices. In general, an endoscopy will have been performed and will have revealed either direct evidence of variceal bleeding (bleeding varix, red wale sign) or historical evidence for significant upper gastro-intestinal bleeding plus upper endoscopy revealing moderate varices and no other site of bleeding is identified</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="517"/>
                <count group_id="O2" value="533"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Ascites</title>
        <description>Any abdominal fluid which is:
Mild, moderate or marked on ultrasound; or
Progressive on serial physical examinations; or
Requires diuretic therapy. To meet the definition of ascites, abdominal fluid that is “mild” (“barely detectable”) on physical examination requires ultrasound confirmation that is “mild”, “moderate” or “marked” ascites. Ultrasound reports of minimal fluid around the liver do not meet the definition.</description>
        <time_frame>1400 days (3.85 years) post randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Peginterferon Alfa-2a 90 mcg/Week</title>
            <description>Treatment with Peginterferon alfa-2a 90 mcg administered once weekly for an additional 42 months</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care Followup</title>
            <description>Stop any peginterferon alfa-2a/ribavirin therapy and followed prospectively for an additional 42 months without treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Ascites</title>
          <description>Any abdominal fluid which is:
Mild, moderate or marked on ultrasound; or
Progressive on serial physical examinations; or
Requires diuretic therapy. To meet the definition of ascites, abdominal fluid that is “mild” (“barely detectable”) on physical examination requires ultrasound confirmation that is “mild”, “moderate” or “marked” ascites. Ultrasound reports of minimal fluid around the liver do not meet the definition.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="517"/>
                <count group_id="O2" value="533"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Spontaneous Bacterial Peritonitis</title>
        <description>Any episode of spontaneous ascitic infection diagnosed on the basis of elevated neutrophil count (&gt; 250/ml) in paracentesis fluid or positive bacterial cultures and clinical diagnosis in the absence of white blood cell (WBC) availability.</description>
        <time_frame>1400 days (3.85 years) post randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Peginterferon Alfa-2a 90 mcg/Week</title>
            <description>Treatment with Peginterferon alfa-2a 90 mcg administered once weekly for an additional 42 months</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care Followup</title>
            <description>Stop any peginterferon alfa-2a/ribavirin therapy and followed prospectively for an additional 42 months without treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Spontaneous Bacterial Peritonitis</title>
          <description>Any episode of spontaneous ascitic infection diagnosed on the basis of elevated neutrophil count (&gt; 250/ml) in paracentesis fluid or positive bacterial cultures and clinical diagnosis in the absence of white blood cell (WBC) availability.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="517"/>
                <count group_id="O2" value="533"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Hepatic Encephalopathy</title>
        <description>Any mental status alteration which is deemed by the investigator to be due to portosystemic encephalopathy, whether occurring during a provoked episode (GI bleeding, diuretics, usual sedative doses), or spontaneously (without apparent cause).</description>
        <time_frame>1400 days (3.85 years) post randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Peginterferon Alfa-2a 90 mcg/Week</title>
            <description>Treatment with Peginterferon alfa-2a 90 mcg administered once weekly for an additional 42 months</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care Followup</title>
            <description>Stop any peginterferon alfa-2a/ribavirin therapy and followed prospectively for an additional 42 months without treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Hepatic Encephalopathy</title>
          <description>Any mental status alteration which is deemed by the investigator to be due to portosystemic encephalopathy, whether occurring during a provoked episode (GI bleeding, diuretics, usual sedative doses), or spontaneously (without apparent cause).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="517"/>
                <count group_id="O2" value="533"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serious Adverse Events</title>
        <description>A serious adverse event (SAE) is an untoward medical occurrence that results in any of the following:
Death
Is life threatening (risk of death at the time of the event)
Requires in-patient hospitalization or prolongation of existing hospitalization
Results in persistent or significant disability/incapacity
Congenital abnormality or birth defect
Trial outcomes (except death) were not considered serious adverse events.</description>
        <time_frame>1400 days (3.85 years) post randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Peginterferon Alfa-2a 90 mcg/Week</title>
            <description>Treatment with Peginterferon alfa-2a 90 mcg administered once weekly for an additional 42 months</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care Followup</title>
            <description>Stop any peginterferon alfa-2a/ribavirin therapy and followed prospectively for an additional 42 months without treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Serious Adverse Events</title>
          <description>A serious adverse event (SAE) is an untoward medical occurrence that results in any of the following:
Death
Is life threatening (risk of death at the time of the event)
Requires in-patient hospitalization or prolongation of existing hospitalization
Results in persistent or significant disability/incapacity
Congenital abnormality or birth defect
Trial outcomes (except death) were not considered serious adverse events.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="517"/>
                <count group_id="O2" value="533"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="175"/>
                    <measurement group_id="O2" value="155"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Fibrosis From Baseline at Year 2 or Year 4 Biopsy.</title>
        <description>Change in Ishak hepatic fibrosis score (range 0-6, higher score indicates greater fibrosis) by assessment of a liver-biopsy specimen obtained during the study (collected at baseline, Year 2 and Year 4 biopsies, 1.5 and 3.5 years after randomization)</description>
        <time_frame>1400 days (3.85 years) post randomization</time_frame>
        <population>Numbers of participants at 1.5 and 3.5 years are the number with biopsies at those time points</population>
        <group_list>
          <group group_id="O1">
            <title>Peginterferon Alfa-2a 90 mcg/Week</title>
            <description>Treatment with Peginterferon alfa-2a 90 mcg administered once weekly for an additional 42 months</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care Followup</title>
            <description>Stop any peginterferon alfa-2a/ribavirin therapy and followed prospectively for an additional 42 months without treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Fibrosis From Baseline at Year 2 or Year 4 Biopsy.</title>
          <description>Change in Ishak hepatic fibrosis score (range 0-6, higher score indicates greater fibrosis) by assessment of a liver-biopsy specimen obtained during the study (collected at baseline, Year 2 and Year 4 biopsies, 1.5 and 3.5 years after randomization)</description>
          <population>Numbers of participants at 1.5 and 3.5 years are the number with biopsies at those time points</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="430"/>
                <count group_id="O2" value="429"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1.5 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="430"/>
                    <count group_id="O2" value="429"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.07" spread="1.27"/>
                    <measurement group_id="O2" value="-0.09" spread="1.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3.5 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="349"/>
                    <count group_id="O2" value="350"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.12" spread="1.36"/>
                    <measurement group_id="O2" value="0.12" spread="1.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Presumed Hepatocellular Carcinoma (HCC)</title>
        <description>Presumed HCC was considered when histology was not available and alpha-fetoprotein (AFP) is &lt;1000 ng/ml, if:
A new hepatic lesion was shown on ultrasound and 1 additional imaging showed a hepatic lesion with characteristics of HCC.
AFP&gt; upper limit of normal (ULN) and 2 imaging studies showed a hepatic lesion with characteristics of HCC.
A progressively enlarging hepatic lesion starting as a new defect resulting in patient death.
A new hepatic defect with at least 1 characteristic scan and:
Increase in size over time or
Increasing AFP rising to a level of &gt;200 ng/ml</description>
        <time_frame>1400 days (3.85 years) post randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Peginterferon Alfa-2a 90 mcg/Week</title>
            <description>Treatment with Peginterferon alfa-2a 90 mcg administered once weekly for an additional 42 months</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care Followup</title>
            <description>Stop any peginterferon alfa-2a/ribavirin therapy and followed prospectively for an additional 42 months without treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Presumed Hepatocellular Carcinoma (HCC)</title>
          <description>Presumed HCC was considered when histology was not available and alpha-fetoprotein (AFP) is &lt;1000 ng/ml, if:
A new hepatic lesion was shown on ultrasound and 1 additional imaging showed a hepatic lesion with characteristics of HCC.
AFP&gt; upper limit of normal (ULN) and 2 imaging studies showed a hepatic lesion with characteristics of HCC.
A progressively enlarging hepatic lesion starting as a new defect resulting in patient death.
A new hepatic defect with at least 1 characteristic scan and:
Increase in size over time or
Increasing AFP rising to a level of &gt;200 ng/ml</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="517"/>
                <count group_id="O2" value="533"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SF-36 Vitality Summary Score</title>
        <description>Change from baseline to years 0.5, 1.5, 2.5, and 3.5 in Short Form Health Survey (SF-36) Vitality summary score. The SF-36 Vitality summary score is the sum of 4 individual scores. It is scaled from 0 to 100 with a score of 0 equivalent to maximum disability and a score of 100 equivalent to no disability. A negative value indicates a decrease in quality of life from baseline.</description>
        <time_frame>0.5, 1.5, 2.5, and 3.5 years after randomization</time_frame>
        <population>At each visit the analysis population is the number who completed the questionaire</population>
        <group_list>
          <group group_id="O1">
            <title>Peginterferon Alfa-2a 90 mcg/Week</title>
            <description>Treatment with Peginterferon alfa-2a 90 mcg administered once weekly for an additional 42 months</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care Followup</title>
            <description>Stop any peginterferon alfa-2a/ribavirin therapy and followed prospectively for an additional 42 months without treatment</description>
          </group>
        </group_list>
        <measure>
          <title>SF-36 Vitality Summary Score</title>
          <description>Change from baseline to years 0.5, 1.5, 2.5, and 3.5 in Short Form Health Survey (SF-36) Vitality summary score. The SF-36 Vitality summary score is the sum of 4 individual scores. It is scaled from 0 to 100 with a score of 0 equivalent to maximum disability and a score of 100 equivalent to no disability. A negative value indicates a decrease in quality of life from baseline.</description>
          <population>At each visit the analysis population is the number who completed the questionaire</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="517"/>
                <count group_id="O2" value="533"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0.5 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="487"/>
                    <count group_id="O2" value="492"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.05" spread="20.5"/>
                    <measurement group_id="O2" value="-1.61" spread="19.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1.5 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="468"/>
                    <count group_id="O2" value="471"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.40" spread="20.31"/>
                    <measurement group_id="O2" value="-3.24" spread="20.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2.5 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="436"/>
                    <count group_id="O2" value="430"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.68" spread="21.71"/>
                    <measurement group_id="O2" value="-2.97" spread="19.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3.5 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="226"/>
                    <count group_id="O2" value="214"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.69" spread="19.83"/>
                    <measurement group_id="O2" value="-3.27" spread="23.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SF-36 Physical Function Summary Score</title>
        <description>Change from baseline to years 0.5, 1.5, 2.5, and 3.5 in Short Form Health Survey (SF-36) Physical Function summary score. The SF-36 Physical Function summary score is the sum of 10 individual scores. It is scaled from 0 to 100 with a score of 0 equivalent to maximum disability and a score of 100 equivalent to no disability. A negative value indicates a decrease in quality of life from baseline.</description>
        <time_frame>0.5, 1.5, 2.5, and 3.5 years after randomization</time_frame>
        <population>At each visit the analysis population is the number who completed the questionaire</population>
        <group_list>
          <group group_id="O1">
            <title>Peginterferon Alfa-2a 90 mcg/Week</title>
            <description>Treatment with Peginterferon alfa-2a 90 mcg administered once weekly for an additional 42 months</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care Followup</title>
            <description>Stop any peginterferon alfa-2a/ribavirin therapy and followed prospectively for an additional 42 months without treatment</description>
          </group>
        </group_list>
        <measure>
          <title>SF-36 Physical Function Summary Score</title>
          <description>Change from baseline to years 0.5, 1.5, 2.5, and 3.5 in Short Form Health Survey (SF-36) Physical Function summary score. The SF-36 Physical Function summary score is the sum of 10 individual scores. It is scaled from 0 to 100 with a score of 0 equivalent to maximum disability and a score of 100 equivalent to no disability. A negative value indicates a decrease in quality of life from baseline.</description>
          <population>At each visit the analysis population is the number who completed the questionaire</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="517"/>
                <count group_id="O2" value="533"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0.5 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="483"/>
                    <count group_id="O2" value="485"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.64" spread="8.66"/>
                    <measurement group_id="O2" value="-0.97" spread="8.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1.5 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="460"/>
                    <count group_id="O2" value="467"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.41" spread="9.10"/>
                    <measurement group_id="O2" value="-1.63" spread="9.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2.5 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="434"/>
                    <count group_id="O2" value="426"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.99" spread="9.87"/>
                    <measurement group_id="O2" value="-1.68" spread="9.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3.5 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="223"/>
                    <count group_id="O2" value="213"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.80" spread="9.56"/>
                    <measurement group_id="O2" value="-1.66" spread="9.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SF-36 Mental Health Summary Score</title>
        <description>Change from baseline to years 0.5, 1.5, 2.5, and 3.5 in Short Form Health Survey (SF-36) Mental Health summary score. The SF-36 Mental Health summary score is the sum of 5 individual scores. It is scaled from 0 to 100 with a score of 0 equivalent to maximum disability and a score of 100 equivalent to no disability. A negative value indicates a decrease in quality of life from baseline.</description>
        <time_frame>0.5, 1.5, 2.5, and 3.5 years after randomization</time_frame>
        <population>At each visit the analysis population is the number who completed the questionaire</population>
        <group_list>
          <group group_id="O1">
            <title>Peginterferon Alfa-2a 90 mcg/Week</title>
            <description>Treatment with Peginterferon alfa-2a 90 mcg administered once weekly for an additional 42 months</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care Followup</title>
            <description>Stop any peginterferon alfa-2a/ribavirin therapy and followed prospectively for an additional 42 months without treatment</description>
          </group>
        </group_list>
        <measure>
          <title>SF-36 Mental Health Summary Score</title>
          <description>Change from baseline to years 0.5, 1.5, 2.5, and 3.5 in Short Form Health Survey (SF-36) Mental Health summary score. The SF-36 Mental Health summary score is the sum of 5 individual scores. It is scaled from 0 to 100 with a score of 0 equivalent to maximum disability and a score of 100 equivalent to no disability. A negative value indicates a decrease in quality of life from baseline.</description>
          <population>At each visit the analysis population is the number who completed the questionaire</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="517"/>
                <count group_id="O2" value="533"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0.5 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="483"/>
                    <count group_id="O2" value="485"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.62" spread="9.58"/>
                    <measurement group_id="O2" value="-1.08" spread="9.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1.5 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="460"/>
                    <count group_id="O2" value="467"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.22" spread="9.68"/>
                    <measurement group_id="O2" value="-1.67" spread="9.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2.5 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="434"/>
                    <count group_id="O2" value="426"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.65" spread="10.17"/>
                    <measurement group_id="O2" value="-2.15" spread="10.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3.5 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="223"/>
                    <count group_id="O2" value="213"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.84" spread="9.56"/>
                    <measurement group_id="O2" value="-1.85" spread="10.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Within 1400 days (3.83 years) after randomization</time_frame>
      <desc>In the treatment group, 3991 adverse events occurred among 486 patients, as compared with 3129 adverse events among 492 patients in the control group; 330 patients had at least one serious adverse event.</desc>
      <group_list>
        <group group_id="E1">
          <title>Peginterferon Alfa-2a 90 mcg/Week</title>
          <description>Treatment with Peginterferon alfa-2a 90 mcg administered once weekly for an additional 42 months</description>
        </group>
        <group group_id="E2">
          <title>Standard of Care Followup</title>
          <description>Stop any peginterferon alfa-2a/ribavirin therapy and followed prospectively for an additional 42 months without treatment</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="175" subjects_at_risk="517"/>
                <counts group_id="E2" subjects_affected="155" subjects_at_risk="533"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="517"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="533"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia or pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="517"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="533"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atherosclerotic disease</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="517"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="533"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="517"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="533"/>
              </event>
              <event>
                <sub_title>Other cardiovascular or circulatory event</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="517"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="533"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Electrolyte, mineral, or water imbalance</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="517"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="533"/>
              </event>
              <event>
                <sub_title>Diabetes and its complications</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="517"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="533"/>
              </event>
              <event>
                <sub_title>Thyroid disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="517"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="533"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nonvariceal gastrointestinal bleeding</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="517"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="533"/>
              </event>
              <event>
                <sub_title>Hernia or intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="517"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="533"/>
              </event>
              <event>
                <sub_title>Other digestive system event</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="517"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="533"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiovascular signs or symptoms</sub_title>
                <description>These clinical signs and symptoms are not associated with a specific diagnosis but are still classified as a serious adverse event.</description>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="517"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="533"/>
              </event>
              <event>
                <sub_title>Hepatobiliary signs or symptoms</sub_title>
                <description>These clinical signs and symptoms are not associated with a specific diagnosis but are still classified as a serious adverse event.</description>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="517"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="533"/>
              </event>
              <event>
                <sub_title>Neurologic signs or symptoms</sub_title>
                <description>These clinical signs and symptoms are not associated with a specific diagnosis but are still classified as a serious adverse event.</description>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="517"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="533"/>
              </event>
              <event>
                <sub_title>Digestive signs or symptoms</sub_title>
                <description>These clinical signs and symptoms are not associated with a specific diagnosis but are still classified as a serious adverse event.</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="517"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="533"/>
              </event>
              <event>
                <sub_title>Other general signs or symptoms</sub_title>
                <description>These clinical signs and symptoms are not associated with a specific diagnosis but are still classified as a serious adverse event.</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="517"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="533"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Gallbladder disease</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="517"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="533"/>
              </event>
              <event>
                <sub_title>Other pancreatic or biliary disorders</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="517"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="533"/>
              </event>
              <event>
                <sub_title>Liver-disease events other than primary or secondary outcomes</sub_title>
                <description>Liver-disease events not related to death or other study-related clinical primary or secondary outcomes of the trial</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="517"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="533"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Mucocutaneous infection and infectious diseases</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="517"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="533"/>
              </event>
              <event>
                <sub_title>Respiratory tract infections and infectious diseases</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="517"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="533"/>
              </event>
              <event>
                <sub_title>Systemic infections and infectious diseases</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="517"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="533"/>
              </event>
              <event>
                <sub_title>Other infections and infectious diseases</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="517"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="533"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="517"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="533"/>
              </event>
              <event>
                <sub_title>Drug reaction</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="517"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="533"/>
              </event>
              <event>
                <sub_title>Liver-biopsy complication</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="517"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="533"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskelatal surgery</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="517"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="533"/>
              </event>
              <event>
                <sub_title>Arthritis or back pain</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="517"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="533"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Malignant neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="517"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="533"/>
              </event>
              <event>
                <sub_title>Benign neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="517"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="533"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral aneurysm, infarct, or stroke</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="517"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="533"/>
              </event>
              <event>
                <sub_title>Other neurologic event</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="517"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="533"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Affective disorders or delirium</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="517"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="533"/>
              </event>
              <event>
                <sub_title>Suicidal ideation or attempt</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="517"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="533"/>
              </event>
              <event>
                <sub_title>Substance abuse</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="517"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="533"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal or urinary diseases</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="517"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="533"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Gynecologic, menstrual, or sexual disorders</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="517"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="533"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory disorders</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="517"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="533"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Benign skin and nail disorders</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="517"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="533"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="486" subjects_at_risk="517"/>
                <counts group_id="E2" subjects_affected="492" subjects_at_risk="533"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="517"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="533"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="517"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="533"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="517"/>
                <counts group_id="E2" subjects_affected="56" subjects_at_risk="533"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="517"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="533"/>
              </event>
              <event>
                <sub_title>Diarrhea, loose stool</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="517"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="533"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="517"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="533"/>
              </event>
              <event>
                <sub_title>Dizziness, vertigo, light-headedness</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="517"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="533"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="77" subjects_at_risk="517"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="533"/>
              </event>
              <event>
                <sub_title>Insomnia, sleep disturbance</sub_title>
                <counts group_id="E1" subjects_affected="92" subjects_at_risk="517"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="533"/>
              </event>
              <event>
                <sub_title>Memory loss, confusion</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="517"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="533"/>
              </event>
              <event>
                <sub_title>Tingling, numbness</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="517"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="533"/>
              </event>
              <event>
                <sub_title>Nervousness, irritability</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="517"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="533"/>
              </event>
              <event>
                <sub_title>Nonproductive cough</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="517"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="533"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="517"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="533"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="71" subjects_at_risk="517"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="533"/>
              </event>
              <event>
                <sub_title>Body aches, chills, fever</sub_title>
                <counts group_id="E1" subjects_affected="86" subjects_at_risk="517"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="533"/>
              </event>
              <event>
                <sub_title>Fatigue, malaise, weakness</sub_title>
                <counts group_id="E1" subjects_affected="141" subjects_at_risk="517"/>
                <counts group_id="E2" subjects_affected="121" subjects_at_risk="533"/>
              </event>
              <event>
                <sub_title>Localized edema</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="517"/>
                <counts group_id="E2" subjects_affected="64" subjects_at_risk="533"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="136" subjects_at_risk="517"/>
                <counts group_id="E2" subjects_affected="134" subjects_at_risk="533"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="517"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="533"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cystitis, bladder infection</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="517"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="533"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="517"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="533"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="517"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="533"/>
              </event>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="517"/>
                <counts group_id="E2" subjects_affected="57" subjects_at_risk="533"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="136" subjects_at_risk="517"/>
                <counts group_id="E2" subjects_affected="119" subjects_at_risk="533"/>
              </event>
              <event>
                <sub_title>Bursitis, tendonitis, enthesopathies</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="517"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="533"/>
              </event>
              <event>
                <sub_title>Limb pain</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="517"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="533"/>
              </event>
              <event>
                <sub_title>Muscle spasm</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="517"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="533"/>
              </event>
              <event>
                <sub_title>Muscle/back aches or pain</sub_title>
                <counts group_id="E1" subjects_affected="145" subjects_at_risk="517"/>
                <counts group_id="E2" subjects_affected="124" subjects_at_risk="533"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="517"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="533"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="93" subjects_at_risk="517"/>
                <counts group_id="E2" subjects_affected="89" subjects_at_risk="533"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Sexual dysfunction, impotence</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="517"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="533"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="517"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="533"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritis</sub_title>
                <counts group_id="E1" subjects_affected="93" subjects_at_risk="517"/>
                <counts group_id="E2" subjects_affected="70" subjects_at_risk="533"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>James E. Everhart, MD, MPH, Project Officer</name_or_title>
      <organization>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</organization>
      <phone>301-594-8878</phone>
      <email>EverhartJ@extra.niddk.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

